Metavia Inc Quick Ratio (MTVA) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Metavia Inc   (NASDAQ: MTVA)

Metavia Inc 's Quick Ratio

MTVA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.99 below Metavia Inc average.

Within Major Pharmaceutical Preparations industry 290 other companies have achieved higher Quick Ratio than Metavia Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 921 to 1268.

Explain Quick Ratio?
How much Cash & cash equivalents MTVA´s has?
What are MTVA´s Current Liabilities?




MTVA Quick Ratio (Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
(Jun 30 2025)
Q2
Y / Y Current Liabilities Change -28.05 % 70.01 % -31.71 % -7.46 % -9.18 %
Y / Y Cash & cash equivalent Change -28.16 % 22.71 % -35.83 % -34.11 % -37.03 %
Quick Ratio MRQ 1.99 2.64 1.82 1.69 1.99
MTVA's Total Ranking # 1268 # 921 # 1211 # 1162 # 926
Seq. Current Liabilities Change 22.23 % -8.07 % -33.03 % -4.38 % 188.8 %
Seq. Cash & cash equivalent Change -7.97 % 33.6 % -28.01 % -18.83 % 57.18 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 291
Healthcare Sector # 506
Overall Market # 1268


Quick Ratio Statistics
High Average Low
14.65 4.08 0.49
(Sep 30 2016)   (Jun 30 2016)




Financial Statements
Metavia Inc 's Current Liabilities $ 6 Millions Visit MTVA's Balance sheet
Metavia Inc 's Cash & cash equivalent $ 13 Millions Visit MTVA's Balance sheet
Source of MTVA's Sales Visit MTVA's Sales by Geography


Cumulative Metavia Inc 's Quick Ratio

MTVA's Quick Ratio for the trailling 12 Months

MTVA Quick Ratio

(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -12.44 % -6.82 % -23.48 % 4.63 % 27.65 %
Y / Y Cash & cash equivalent TTM Growth -23.39 % -27.26 % -34.65 % -32.89 % -27.91 %
Quick Ratio TTM 1.99 1.99 2.05 2.07 2.27
Total Ranking TTM # 3822 # 2809 # 2954 # 3152 # 2740
Seq. Current Liabilities TTM Growth -8.81 % 8.24 % -9.18 % -2.32 % -2.96 %
Seq. Cash & cash equivalent TTM Growth -8.86 % 4.76 % -9.72 % -11.12 % -13.47 %


On the trailing twelve months basis In spite of the year on year decrease in MTVA's Current Liabilities to $6.35 millions, cumulative Quick Ratio to 1.99 below the MTVA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Metavia Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2809 to 3822.

Explain Quick Ratio?
How much Cash & cash equivalents MTVA´s has?
What are MTVA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 883
Within the Market # 3822


trailing twelve months Quick Ratio Statistics
High Average Low
7.42 3.57 1.18
(Dec 31 2021)   (Dec 31 2016)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions
Context Therapeutics Inc   5.45 $ 42.990  Millions$ 7.885  Millions
Annexon Inc   5.44 $ 209.200  Millions$ 38.482  Millions
Arbutus Biopharma Corp  5.35 $ 19.172  Millions$ 3.585  Millions
Cns Pharmaceuticals Inc   5.35 $ 19.985  Millions$ 3.738  Millions
Neurogene Inc   5.23 $ 112.485  Millions$ 21.505  Millions
Lexaria Bioscience Corp   5.20 $ 3.642  Millions$ 0.701  Millions
Barinthus Biotherapeutics Plc  5.19 $ 59.295  Millions$ 11.423  Millions
Lite Strategy Inc   5.15 $ 5.706  Millions$ 1.109  Millions
Immuneering Corporation  5.14 $ 41.731  Millions$ 8.116  Millions
BlossomHill Therapeutics, Inc.  5.12 $ 95.376  Millions$ 18.621  Millions
Lyell Immunopharma Inc   5.12 $ 204.102  Millions$ 39.867  Millions
Altimmune inc   5.04 $ 63.008  Millions$ 12.501  Millions
Rani Therapeutics Holdings Inc   5.02 $ 53.391  Millions$ 10.638  Millions
Phio Pharmaceuticals Corp  4.99 $ 12.996  Millions$ 2.606  Millions
Immunic Inc   4.96 $ 155.098  Millions$ 31.260  Millions
Uniqure N v   4.96 $ 413.027  Millions$ 83.345  Millions
Silo Pharma Inc  4.90 $ 5.227  Millions$ 1.066  Millions
Apnimed, Inc.  4.86 $ 172.804  Millions$ 35.578  Millions
Atossa Therapeutics Inc   4.81 $ 26.204  Millions$ 5.451  Millions
Calcimedica Inc   4.71 $ 18.600  Millions$ 3.950  Millions
Kala Bio inc   4.70 $ 7.229  Millions$ 1.538  Millions
Septerna Inc   4.69 $ 372.322  Millions$ 79.316  Millions
Viking Therapeutics Inc   4.57 $ 501.663  Millions$ 109.656  Millions
Camp4 Therapeutics Corporation  4.51 $ 86.398  Millions$ 19.142  Millions
Rein Therapeutics Inc   4.49 $ 43.627  Millions$ 9.709  Millions
Quantum Cyber N v   4.46 $ 13.415  Millions$ 3.005  Millions
Maia Biotechnology Inc   4.41 $ 27.596  Millions$ 6.258  Millions
Azitra Inc   4.40 $ 6.728  Millions$ 1.531  Millions
Cypherpunk Technologies Inc   4.39 $ 7.624  Millions$ 1.737  Millions

Date modified: 2026-09-03T12:02:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.